Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tauqueer Alam

Internal Medicine Seneca, SC Medical Doctor

NPI 1043263494 CMS profile 1443

109 Carter Park Dr, Suite 3A, Seneca, SC 29678

Open in the dashboard

General payments

$1,611

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tauqueer Alam of Seneca, SC is reported in the CMS Open Payments database as having received $1,611 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $302 15
2024 General $257 13
2023 General $179 9
2022 General $153 9
2021 General $402 31
2020 General $142 8
2019 General $177 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tauqueer Alam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Tauqueer Alam were reported at $302. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Tauqueer Alam Internal Medicine median Middle half National median
2019 $177 $159 $48–$570 $163
2020 $142 $119 $33–$402 $114
2021 $402 $135 $37–$521 $132
2022 $153 $141 $42–$496 $149
2023 $179 $149 $45–$519 $160
2024 $257 $154 $47–$537 $164
2025 $302 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $325 23 payments
  2. Novartis Pharmaceuticals Corporation $305 18 payments
  3. Novo Nordisk Inc $185 11 payments
  4. Abbott Laboratories $178 8 payments
  5. AstraZeneca Pharmaceuticals LP $114 8 payments
  6. GlaxoSmithKline, LLC. $65 3 payments
  7. Lilly USA, LLC $64 3 payments
  8. Xeris Pharmaceuticals, Inc. $42 2 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $40 2 payments
  10. Janssen Pharmaceuticals, Inc $35 2 payments
  11. Other $259 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,611 95 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $249 18 payments
  2. ENTRESTO $230 14 payments
  3. Ozempic $168 10 payments
  4. FreeStyle Libre 3 $144 6 payments
  5. RYBELSUS $143 9 payments
  6. TRELEGY ELLIPTA $65 3 payments
  7. MOUNJARO $64 3 payments
  8. BREZTRI $51 4 payments
  9. UBRELVY $43 3 payments
  10. GVOKE HYPOPEN $42 2 payments
  11. Other $738 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

6,425

Median for Internal Medicine: 777

Drug cost

$674,836

Median for Internal Medicine: $73,373

Branded share of claims

27%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 190 $194,253
Mounjaro Tirzepatide Brand 70 $79,284
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 79 $73,096
Eliquis Apixaban Brand 66 $58,409
Entresto Sacubitril/Valsartan Brand 29 $25,008
Xarelto Rivaroxaban Brand 25 $24,191
Tresiba Flextouch U-100 Insulin Degludec Brand 27 $22,282
Farxiga Dapagliflozin Propanediol Brand 19 $22,067
Vraylar Cariprazine Hcl Brand 13 $18,926
Januvia Sitagliptin Phosphate Brand 12 $11,929

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 262 billing codes

Paid by Medicare

$548,318

Of which drugs: $9,404

Medicare patients

690

Average age 73

Services billed

40,330

389 women, 301 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 46%
Heart failure 39%
COPD 38%
Ischemic heart disease 32%
Chronic kidney disease 28%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 54 216 $1,214
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 21 160 $887
Injection, methylprednisolone acetate, 1 mg J1010 Office 86 7,580 $750
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 75 7,891 $739
Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older 90714 Office 11 13 $248
Injection, ceftriaxone sodium, per 250 mg J0696 Office 26 348 $121
Injection, ketorolac tromethamine, per 15 mg J1885 Office 53 215 $110
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 43 111 $106
Infusion, normal saline solution , 1000 cc J7030 Office 25 51 $103
Injection, levofloxacin, 250 mg J1956 Office 17 113 $85

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $50
$50 13 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $37
$37 19 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $21
$21 — —
Veozah
  • Astellas Pharma US Inc $15
$15 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $14
$14 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record